Acme United Corp Dossier
|
SectorHealth Care IndustryHealth Care Supplies Beta (adjusted)0.65 Intrinsic Value $34.63median of 5 methods · middle span $33-$37based on filings through 30 Jun 2026 Market Price $63.42Price as of 30 Sep 2026 OvervaluedIntrinsic value is 45% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $243.1M Enterprise Value $260.7M Shares Outstanding 4.2M diluted Moat Rating Narrow Next Earnings Date20 Oct 2026 Last ex-dividend2 Jul 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Acme United Corporation (ACU) continues to demonstrate solid top-line momentum, driven by strategic acquisitions such as My Medic and steady organic growth in its core first aid and medical segments. However, recent profitability has been heavily pressured by tariff-related costs, supply chain disruptions, and elevated SG&A expenses associated with the integration of My Medic. While the company's long-term outlook remains supported by product innovation (such as the RFID SmartCompliance Cabinet) and automated production investments, the near-term outlook is balanced by margin headwinds and a substantial debt service drag. Consequently, a Hold rating is recommended until sustained margin recovery and organic profitability improvements materialize. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$58.00 Mean target$58.00 High · most bullish analyst$58.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $42.8420% Persistent tariff disruptions and supply chain bottlenecks continue to inflate cost of goods sold. My Medic integration fails to deliver expected cost synergies, resulting in sustained SG&A pressure. High interest expenses drag down net income, leading to further earnings misses and a contraction in valuation multiples. Base CaseCentral scenario $51.0050% Acme United achieves its FY2026 revenue target of $225M-$230M, supported by a mix of organic growth and My Medic contributions. Gross margins stabilize around 39%-40% as tariff impacts gradually ease. SG&A expenses remain slightly elevated due to ongoing integration and marketing costs, keeping near-term earnings growth modest but stable. Bull CaseUpside scenario $53.4730% Successful integration of My Medic drives high-margin direct-to-consumer (D2C) sales and cross-selling opportunities. Rapid adoption of the patented RFID SmartCompliance Cabinet accelerates recurring first-aid replenishment revenue. Easing tariff pressures and automation investments at North American plants expand gross margins beyond 41%, driving significant EPS upside. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |